Publications by authors named "Steve Rose"
Article Synopsis
- The study aimed to evaluate children with epilepsy and motor speech regression by examining their speech disorders, seizure characteristics, and overall outcomes.
- Eighteen children were assessed, revealing speech regression typically starting around age 5, often coinciding with seizures; common speech disorders included dysarthria and phonological errors, along with specific electrographic abnormalities in the brain.
- While the speech intelligibility initially affected many children, those with Landau-Kleffner syndrome showed significant improvement over time, contrasting with a decline in expressive language abilities for children with Rasmussen syndrome; overall, motor speech disorders were complex and severity fluctuated with seizure activity.
In approximately ten months' time, the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 34 million people and caused over one million deaths worldwide. The impact of this virus on our health, relationships, and careers is difficult to overstate. As the economic realities for academic medical centers come into focus, we must recommit to our core missions of patient care, education, and research.
View Article and Find Full Text PDFImportance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited.
Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19.
Design, Setting, And Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin.
Reported are the reduction of anti-HLA antibody levels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, double-blind, placebo-controlled clinical trial. Between 1997 and 2000, a total of 101 adult patients with ESRD who were highly sensitized to HLA antigens (panel reactive antibody [PRA] > or =50% monthly for 3 mo) enrolled onto an NIH-sponsored trial (IG02). Patients received IVIG or placebo.
View Article and Find Full Text PDF